![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:0493U Bespak PLC 14 November 2005 For immediate release 14 November 2005 Bespak plc Trading update for the 26 weeks to 29 October 2005 Bespak plc (LSE: BPK), a leader in specialty medical devices, announces that trading in the first half was in line with its expectations. There has been replenishment of the CFC valve supply chain in the US following the FDA ruling on phase-out of CFC albuterol formulations, continuing growth in HFA valve sales and inventory building by customers of US-manufactured products in advance of closure of the Cary facility. Looking ahead, two key events will continue to influence Bespak's performance. Firstly, customers in the US are continuing to develop their marketing plans for the replacement of CFC with HFA in albuterol formulations by December 2008. Secondly, Bespak awaits the approval of Exubera(R). In September the FDA's clinical advisory panel recommended approval of Exubera(R) in the US, whilst in October the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended approval of Exubera(R) in Europe. In the second half, we expect additional expenditure to strengthen the businesses, general inflationary cost pressures and reversal of inventory building by customers of previously US-manufactured products that have been transferred to the UK, which leads us to be cautious in the short term. However, we are increasingly confident in the prospects for growth from Exubera(R). Bespak will report its interim results on 18 January 2006. For further information, please contact: Bespak plc Tel: +44 (0) 1908 525 241 Mark Throdahl - Chief Executive Martin Hopcroft - Group Finance Director Buchanan Communications Tel: +44 (0) 20 7466 5000 Tim Thompson / Mark Court / Mary-Jane Johnson About Bespak plc Bespak, a specialty medical devices company, is at the forefront of developing new delivery systems for the pharmaceutical industry. The company has a product range covering metered dose inhalers, dry powder devices, actuators and compliance aids. The company also develops and manufactures drug delivery devices for leading global pharmaceutical companies. The group, which has facilities in King's Lynn and Milton Keynes in the UK, is a public company quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com. This information is provided by RNS The company news service from the London Stock Exchange END TSTZGMMMNMZGKZM
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions